---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-005103"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:21:37.151513+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Apellis reports preliminary EMPAVELI FY2021 U.S. net product revenue of ~$15M

## Summary
- Preliminary FY2021 U.S. net product revenue for EMPAVELI ~$15 million (unaudited).
- Over 125 start forms submitted; >95% patient compliance; zero meningococcal infections.
- More than 75% of new EMPAVELI starts are switches from competitor Ultomiris.

## SEC filing metadata
- accession: 0001193125-22-005103
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312522005103/0001193125-22-005103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312522005103/d232021d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-005103
- JSON: https://secwatch.observer/filing/0001193125-22-005103.json
- Plain text: https://secwatch.observer/filing/0001193125-22-005103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.